- CDK4/6 inhibitors in adjuvant therapy of breast cancer2023 | First Faculty of Medicine
- Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial2017 | Publication without faculty affiliation